Influenza virus replication

Ryan DM, Ticehurst J, Dempsey M, Penn CR (1994) Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-iV-acetylneuraminic add) is consistent with extracellular actiivity of viral neuraminidase (sialidase), Antimicrob Agents Chemother 10 2270-2275... 

Von Itzstein M, Wu WY, Kok GB, Pegg MS, Oyason JC, Jin B. et al. Rational design of potent siaidase-based inhibitors of influenza-virus replication. Nature... 

LAIV should not be administered until 48 hours after influenza antiviral therapy has stopped, and influenza antiviral drugs should not be administered for 2 weeks after the administration of LAIV because the antiviral drugs inhibit influenza virus replication. 

Palase P, Compans RW. Inhibition of influenza virus replication in tissue culture 2-deoxy-2,3-dehydro-N-trifluroacetylneuraminic acid (FANA) mechanism of action. J Gen Virol 1976 33 159-163. 

Because of the essential role of sialidase in influenza virus replication and the highly conserved enzyme active-site in influenza viruses A and B, most interest has been focused on the development of selective inhibitors of this enzyme.10 This chapter discusses the tremendous progress that has been made in the discovery of this new class of anti-influenza agents, in addition to some background information to understand the fundamental role of influenza. 

W. M. Kati, D. Montgomery, R. Carrick, L. Gubareva, C. Maring, K. McDaniel, K. Steffy, A. Molla, F. Hayden, D. Kempf, and W. Kohlbrenner, In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication, Antimicrob. Agents Chemother., 46 (2002) 1014-1021. 

The antiviral properties of PAA against Herpes Simplex virus were discovered during routine screening (5), and these compounds also inhibit influenza virus replication (6). While the precise mode of action of PAA and PFA are not known at present, they will inhibit the polymerase enzymes in the two viruses. Two mechanisms for this inhibition appear plausible. 

H. F. White, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, and C. R. Penn, Nature (London), 363, 418 (1993). Rational Design of Potent Sialidase-Based Inhibitors of Influenza Virus Replication. 

In another example of liposome usage, a multivalent display of a C-3-modified sialoside on liposomes has been shown to inhibit influenza virus replication [124]. Hemagglutinin and sialidase are both involved in both glycoproteins, are involved in attachment and detachment of viral particles on the host cell through recognition of sialyl residues. In this case, the C-3-modified sialoside liposome seems to be such a successful inhibitor of viral replication because it successfully targets two different enz)mes that act on multivalent carbohydrate displays. 

Population balance modeling of influenza virus replication in MDCK cells during vaccine production... 

Population Balance Modeling of Influenza Virus Replication... 

Zami 420 triletide. zanamivir [ban] (GR 121167X GG 167) is an JV-acetyIneuraminic acid derivative which acts as a neuraminidase (sialidase) inhibitor. It is an ANTIVIRAL that inhibits influenza virus replication, and has shown promise in phase III trials given by direct inhalation for limitation of the duration and severity of flu symptoms, zankiren hydrochloride zankiren. 

Influenza virus replication in human respiratory epithelial cells is efficiently inhibited by zanamivir. Little, if any, cytotoxicity has been reported... 

---